T cells

[CRISPR Therapeutics] CRISPR Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy designation to CTX110™, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.

[Proceedings of the National Academy of Sciences of the United States of America] The authors reported that RORC2 was a key host cofactor for HIV replication in Th17 cells. They found that specific inhibitors that bound to the RORC2 ligand-binding domain reduced HIV replication in CD4+ T cells.

[Nature Communications] Investigators reported that intranasal vaccinations with adenovirus 5 and 19a vectored vaccines following a systemic plasmid DNA or mRNA priming resulted in systemic and mucosal immunity in mice.

[Life Sciences] Scientists inhibited two of the most important immune checkpoints expressed on T cells infiltrated in tumors, including PD-1 and A2aR. Ligation of PD-1 with PD-L1 and A2aR with adenosine significantly suppress T cell responses against tumor cells.

[BMC Medicine] The effect of combined SFN and CAR-T cells was determined in vitro using a co-culture system and in vivo using a xenograft mouse model. They furthered validated the effects of combination therapy in patients with cancer.

[Nature Reviews Immunology] Scientists discuss novel latency-reversing agents targeting DCs as well as DC-based strategies to enhance the clearance of infected cells by CD8+ T cells and strategies to improve the killing activity of natural killer cells.